Postdoctoral Fellow - Computational Biology / Research Oncology, Yao/de Sauvage Lab
Roche
Summary
We seek a highly motivated candidate for a joint postdoctoral fellowship position in the laboratories of Dr. Xiaosai Yao in the Computational Sciences Center of Excellence and Dr. Frederic de Sauvage in the Department of Research Oncology at Genentech. The Yao lab develops and applies computational tools to understand chromatin changes in cancer biology and drug response. The de Sauvage Lab explores mechanisms by which cancer signaling pathways drive tumor growth, metastasis and resistance to treatment with targeted therapies.
Job description
The Opportunity
This hybrid computational and wet lab based postdoctoral position will investigate the interactions between oncogenic pathways and lineage factors, specifically how the underlying chromatin landscape in tissues affects the oncogenic properties of the same driver mutations in different tissues and cells of origin. Mechanisms derived from in vivo cancer models will be used to interpret patient responses to cancer therapeutics across various indications.
- Utilize in vivo cancer models to understand changes in the chromatin after the acquisition of driver mutations and/or treatment with cancer therapeutics.
- Analyze single cell and bulk omics datasets to form hypotheses and derive biological insights.
- Learn best practices in data analysis and potentially software development.
- Collaborate effectively within an interdisciplinary team of quantitative, experimental, and clinical scientists.
- Present complex results clearly and concisely to diverse audiences.
Who You Are
- Ph.D. in Cancer Biology, Computational Biology or related field
- Experience with in vivo cancer models (e.g. GEMM, xenograft) and in vitro cancer assays.
- Experience with bulk and/or single-cell omics data analysis (e.g. bulk RNA-seq, ATAC-seq, ChIP-seq and single-cell RNA-seq/ATAC-seq)
- Proficiency in R or Python is required
- Demonstrated ability to drive at least one key research project, as evidenced by first-author publications in high-impact journals
- Strong communication skills and ability to work in a team environment.
Requirements
- Ph.D. in Cancer Biology, Computational Biology or related field
- Experience with in vivo cancer models (e.g. GEMM, xenograft) and in vitro cancer assays
- Experience with bulk and/or single-cell omics data analysis (e.g. bulk RNA-seq, ATAC-seq, ChIP-seq and single-cell RNA-seq/ATAC-seq)
- Proficiency in R or Python is required
- Demonstrated ability to drive at least one key research project, as evidenced by first-author publications in high-impact journals
- Strong communication skills and ability to work in a team environment
Benefits
- Relocation benefits
- Professional development workshops
- Networking opportunities
- Mentorship
Company overview
Roche is a Swiss multinational healthcare company and a global pioneer in pharmaceuticals and diagnostics, founded in 1896 and headquartered in Basel, Switzerland. As the world's largest biotech company and the fifth-largest pharmaceutical company by revenue, Roche operates through two primary divisions: Pharmaceuticals and Diagnostics. The company is renowned for its leadership in personalized healthcare, combining strengths in both drug development and diagnostic testing to deliver tailored treatments for patients. Roche maintains a strong focus on oncology, immunology, infectious diseases, ophthalmology, and central nervous system disorders, with a portfolio that includes over 30 medicines on the World Health Organization's Model Lists of Essential Medicines. The company owns significant subsidiaries including Genentech, Chugai Pharmaceuticals, Ventana Medical Systems, and Foundation Medicine. With approximately 103,000 employees worldwide and operations in over 100 countries, Roche has established itself as a leader in cancer treatments globally while maintaining a robust pipeline of innovative therapies and diagnostic solutions. The company's commitment to sustainability has been recognized through ten consecutive years as Group Leader in the Dow Jones Sustainability Indices within the Pharmaceuticals, Biotechnology & Life Sciences Industry.